REG - ReNeuron Group plc - Retinal clinical trial progresses to next stage

ReNeuronAnnouncement

18/03/2019 07:05

RNS Number : 1363T
ReNeuron Group plc
18 March 2019
 


 




18 March 2019


AIM: RENE




 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Retinal clinical trial progresses to next stage
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce a further update on progress with the ongoing Phase I/II clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
 
The Company is pleased to report that, following a positive Data Safety Monitoring Board (DSMB) review of the clinical data from the first Phase II patient cohort in the study, dosing of the second cohort of three Phase II subjects has now commenced, with the first subject in the cohort treated last week at Massachusetts Eye and Ear, in Boston.  This next dose cohort comprises patients who have a greater baseline level of visual acuity than those treated in the study thus far, thus providing a framework to better evaluate the safety of the treatment and to gain further clarity on the strong efficacy signal that was seen in the first Phase II cohort.
 
Last month, the Company reported that all three of the first cohort of subjects in the Phase II part of the study had reported a rapid and significant improvement in vision, on average equivalent to reading an additional three lines of 5 letters on the EDTRS eye chart, the standardised eye chart used in clinical trials to measure visual acuity.
 
The Company's RP clinical programme benefits from Orphan Drug Designation in both Europe and the US, as well as Fast Track designation from the FDA.  As previously reported, the Company expects to report further short term read-outs in mid-2019 from the ongoing Phase I/II study. 
 
Olav Hellebø, Chief Executive Officer of ReNeuron, said:
 
"We remain extremely encouraged by the positive efficacy data we have seen thus far in the Phase I/II study with our hRPC cell therapy candidate in RP patients.  These results have already attracted considerable interest, particularly from those in the ophthalmology field, and we look forward to reporting further results from the study as it progresses over the coming months."
 
ENDS
 
ENQUIRIES:
 




ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer


 




Michael Hunt, Chief Financial Officer


 




Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham


 




Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


 




Nplus1 Singer Advisory LLP


+44 (0) 20 7496 3000




Mark Taylor (Joint Broker)


 




 
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  
 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCQVLBFKXFXBBV